Página InicialGruposDiscussãoMaisZeitgeist
Pesquisar O Sítio Web
Este sítio web usa «cookies» para fornecer os seus serviços, para melhorar o desempenho, para analítica e (se não estiver autenticado) para publicidade. Ao usar o LibraryThing está a reconhecer que leu e compreende os nossos Termos de Serviço e Política de Privacidade. A sua utilização deste sítio e serviços está sujeita a essas políticas e termos.
Hide this

Resultados dos Livros Google

Carregue numa fotografia para ir para os Livros Google.

Bad Blood: Secrets and Lies in a Silicon…
A carregar...

Bad Blood: Secrets and Lies in a Silicon Valley Startup (edição 2020)

por John Carreyrou (Autor)

MembrosCríticasPopularidadeAvaliação médiaMenções
1,7791277,343 (4.29)83
"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--… (mais)
Membro:KateFinney
Título:Bad Blood: Secrets and Lies in a Silicon Valley Startup
Autores:John Carreyrou (Autor)
Informação:Vintage (2020), Edition: New, 368 pages
Colecções:A sua biblioteca
Avaliação:****
Etiquetas:Nenhum(a)

Pormenores da obra

Bad Blood: Secrets and Lies in a Silicon Valley Startup por John Carreyrou

A carregar...

Adira ao LibraryThing para descobrir se irá gostar deste livro.

Ainda não há conversas na Discussão sobre este livro.

» Ver também 83 menções

Mostrando 1-5 de 127 (seguinte | mostrar todos)
Scary things in this book:
*Patients were harmed
*The complete lack of ethics by Elizabeth Holmes and Sunny Balwani and those who enabled them
*The pure sloppiness of those in charge, the employees and the board members
*How many investors and board members would invest millions without doing the due diligence to verify their investments--including George Schulz, Rupert Murdoch, Henry Kissinger, and James Mattis. (I guess if you are a billionaire throwing away $100M is fine).
*How companies such as CVS and Safeway could invest millions in a partnership--even changing their store layout to build wellness centers without due diligence. (I always wondered why my Safeway took floor space away to build what looks like a clinic/spa).
*Why there aren't more protections for employee whistleblowers and maybe we've gone too far with NDA protections if it means this type of fraud can go on for years. ( )
  auldhouse | Sep 30, 2021 |
I listened to the audiobook, and I was pretty entertained by the story.
John Carreyrou has done a great job writing the book, the flow of the story is attracting and I only felt bored a few times in the midst of the book, but focusing on what I was hearing the rest of the time.
( )
  mdibaiee | Sep 23, 2021 |
As I write this review, Elizabeth Holmes is on trial in U.S. federal court for fraud—a situation which is entirely unsurprising, having read John Carreyrou's Bad Blood. At its peak, the tech start-up which she once ran, Theranos, was valued at $9bn, but as Carreyrou shows that valuation was based on nothing more than bullshit.

Much has been made in the media about Holmes' wide-eyed stare, artificially deepened voice, and penchant for cosplaying Steve Jobs. Anecdotes about this crop up quite a bit in Bad Blood. What I found much more interesting—and what I wish Carreyrou had hammered home a bit more—was how much the story of Theranos is an indictment of systemic issues. Holmes is fundamentally a fairly boring, run-of-the-mill sociopath—she wants money and adulation and doesn't much care who she has to step on along the way in order to get it.

But most sociopaths don't end up on the cover of Forbes by the time they're 30. The real story here is that Holmes attended a private high school in Texas and dropped out of Stanford; the people she got to know along the way allowed her to get a Who's Who of terrible human beings to invest in her company, including Henry Kissinger, Rupert Murdoch, the Waltons, and Betsy DeVos. Holmes leveraged the prestige of her expensive education and wealthy connections, the greed of those who valued dollar signs more than human lives, and the anti-intellectual narcissism of those who believe that "disruption" is a greater good than expertise and common sense. In 2021—a year when people are choosing to ingest veterinary-grade dewormers and shit their brains out rather than take a free, safe vaccination—this is the part that resonates more deeply than the schadenfreude of it all. ( )
  siriaeve | Sep 4, 2021 |
Absolutely amazing.... I couldn't believe half of the stuff I read and researched it myself. I am stonished at hw could this happen in this era.... ( )
  Douna1980 | Sep 3, 2021 |
This book should go in the true-crime category, since that is what it is. Truly, it's a shocker. You'll never look at the healthcare industry the same way again. Or at lawyers, for that matter. But then, you never really liked lawyers much, did you? ( )
  booklove54 | Jul 25, 2021 |
Mostrando 1-5 de 127 (seguinte | mostrar todos)
sem críticas | adicionar uma crítica

» Adicionar outros autores

Nome do autorPapelTipo de autorObra?Estado
John Carreyrouautor principaltodas as ediçõescalculated
Damron, WillNarradorautor secundárioalgumas ediçõesconfirmado
Tem de autenticar-se para poder editar dados do Conhecimento Comum.
Para mais ajuda veja a página de ajuda do Conhecimento Comum.
Título canónico
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Título original
Títulos alternativos
Data da publicação original
Pessoas/Personagens
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Locais importantes
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Acontecimentos importantes
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Filmes relacionados
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Prémios e menções honrosas
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Epígrafe
Dedicatória
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
For Molly, Sebastian, Jack, and Francesca
Primeiras palavras
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Tim Kemp had good news for his team.
Citações
Últimas palavras
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
(Carregue para mostrar. Atenção: Pode conter revelações sobre o enredo.)
Nota de desambiguação
Editores da Editora
Autores de citações elogiosas (normalmente na contracapa do livro)
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
Língua original
Informação do Conhecimento Comum em inglês. Edite para a localizar na sua língua.
DDC/MDS canónico
Canonical LCC

Referências a esta obra em recursos externos.

Wikipédia em inglês

Nenhum(a)

"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--

Não foram encontradas descrições de bibliotecas.

Descrição do livro
Resumo Haiku

Capas populares

Ligações Rápidas

Avaliação

Média: (4.29)
0.5
1 8
1.5
2 5
2.5 1
3 58
3.5 29
4 228
4.5 57
5 268

É você?

Torne-se num Autor LibraryThing.

 

Acerca | Contacto | LibraryThing.com | Privacidade/Termos | Ajuda/Perguntas Frequentes | Blogue | Loja | APIs | TinyCat | Bibliotecas Legadas | Primeiros Críticos | Conhecimento Comum | 163,163,989 livros! | Barra de topo: Sempre visível